Dr Andreas Rummelt, pharma industry expert and former CEO of Sandoz, was elected as a new supervisory board member at Leukocare's annual shareholder meeting on 12 July
Leukocare, a provider of stabilising and protecting formulation technologies for biopharmaceuticals such as biologics and vaccines, announces the election of Dr Andreas Rummelt as the new member of its supervisory board.
Together with Dr Jean-Paul Prieels, who held various executive positions at GlaxoSmithKline, former Sandoz CEO Dr Rummelt is the second former executive from big pharma on the Leukocare board.
Dr Rummelt's international career included multiple executive positions within Sandoz and Novartis during which he focused on the areas of manufacturing, quality and technical development of pharmaceutical originals and generics. He has served more than 20 years in executive management positions in the industry.
He joined Sandoz Pharma in 1985 in Switzerland and was CEO of Sandoz, the Generics Division of Novartis, in Vienna, Austria and Holzkirchen, Germany, from 2004 to 2008.
Today, Dr Rummelt is Managing Partner with InterPharmaLink, a Basel-based consulting firm to pharma, biotech, generics and other healthcare sectors. He holds various board seats in public and private companies, with Alexion Pharmaceuticals, Alvogen and Xellia Pharmaceuticals, for example.
'We are very pleased that Dr Rummelt is joining our supervisory board,' said Michael Scholl, CEO of Leukocare. 'We are sure that his expertise and network in the industry will support our strategy to become an even stronger player in the field of pharmaceutical formulation development to offer outstanding solutions for biopharmaceutical products,' he added.
'I am looking forward to supporting the company's further development and the roll out of the technology in the pharma industry,' stated Dr Rummelt. 'I am convinced that Leukocare's SPS formulation technology platform has the potential to improve products regarding thermal stability and shelf-life, both for new entities as well as for lifecycle products and biosimilars.'